@article{730a3b3285ba4e7e93f49bf1da1de60f,
title = "Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers",
abstract = "Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.",
keywords = "Adult, Aged, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Carcinoma, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Drug Therapy, Combination, Female, Follow-Up Studies, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Prospective Studies, Quinazolines, Receptor, Epidermal Growth Factor, Survival Analysis, Treatment Outcome",
author = "Rohrberg, {Kristoffer S} and Olesen, {Ren{\'e} K} and Per Pfeiffer and Morten Ladekarl and Helle Pappot and Christensen, {Ib J} and Gunilla H{\o}yer-Hansen and Morten S{\o}rensen and Skov, {Birgit G} and Ian Buysschaert and Peter Carmeliet and Ulrik Lassen",
year = "2012",
month = feb,
doi = "10.3109/0284186X.2011.619568",
language = "English",
volume = "51",
pages = "234--42",
journal = "Acta oncologica (Stockholm, Sweden)",
issn = "1502-3850",
publisher = "Taylor & Francis",
number = "2",
}